Skip to main content
. 2023 Aug 9;18(10):1321–1332. doi: 10.2215/CJN.0000000000000248

Table 3.

Sensitivities and specificities for candidate criteria for unassisted fistula maturation

Time Frame 3 mo 4 mo 5 mo 6 mo 9 mo
Performance Characteristic Sens. Spec. AUC (95% CI) Sens. Spec. AUC (95% CI) Sens. Spec. AUC (95% CI) Sens. Spec. AUC (95% CI) Sens. Spec. AUC (95% CI)
%
(95% CI)
TP/(TP+FN)
%
(95% CI)
TN/(TN+FP)
%
(95% CI)
TP/(TP+FN)
%
(95% CI)
TN/(TN+FP)
%
(95% CI)
TP/(TP+FN)
%
(95% CI)
TN/(TN+FP)
%
(95% CI)
TP/(TP+FN)
%
(95% CI)
TN/(TN+FP)
%
(95% CI)
TP/(TP+FN)
%
(95% CI)
TN/(TN+FP)
HFM 61
(55 to 66)
179/296
100
(99 to 100)
239/239
0.80 (0.77 to 0.83) 79
(74 to 84)
234/296
100
(99 to 100)
239/239
0.90 (0.87 to 0.92) 90
(86 to 93)
234/296
100
(98 to 100)
239/239
0.95 (0.93 to 0.97) 94
(90 to 96)
234/296
100
(99 to 100)
239/239
0.97 (0.95 to 0.98) Ref Ref Ref
NAVAC 63
(57 to 68)
186/296
96
(93 to 98)
230/239
0.80 (0.77 to 0.83) 76
(70 to 81)
224/296
95
(92 to 98)
228/239
0.86 (0.83 to 0.88) 84
(80 to 88)
249/296
95
(91 to 97)
227/239
0.90 (0.87 to 0.92) 86
(81 to 90)
254/296
95
(91 to 97)
227/239
0.90 (0.88 to 0.93) 90
(86 to 93)
267/296
94
(90 to 97)
225/239
0.92 (0.90 to 0.94)
KHI 75
(69 to 80)
221/296
88
(83 to 92)
210/239
0.81 (0.78 to 0.8) 86
(81 to 88)
253/296
86
(81 to 90)
206/239
0.86 (0.83 to 0.89) 94
(91 to 97)
279/296
86
(81 to 90)
206/239
0.90 (0.88 to 0.93) 97
(94 to 99)
287/296
86
(81 to 90)
206/239
0.92 (0.89 to 0.94) 100
(99 to 100)
296/296
85
(80 to 89)
203/239
0.92 (0.90 to 0.95)
No use of alternative vascular access for ≥1 mo 62
(56 to 68)
184/296
96
(92 to 98)
229/239
0.79 (0.76 to 0.82) 78
(73 to 83)
232/296
95
(92 to 98)
228/239
0.87 (0.84 to 0.90) 89
(85 to 92)
263/296
95
(92 to 98)
228/239
0.92 (0.90 to 0.94) 93
(89 to 95)
274/296
95
(92 to 98)
228/239
0.94 (0.92 to 0.96) 97
(94 to 99)
287/296
95
(91 to 97)
226/239
0.96 (0.94 to 0.98)
Four consecutive uses of fistula with BPS ≥300 ml/min 57
(51 to 63)
168/296
98
(96 to 100)
235/239
0.78 (0.75 to 0.80) 74
(69 to 79)
220/296
98
(95 to 99)
234/239
0.86 (0.83 to 0.89) 85
(81 to 89)
252/296
98
(95 to 99)
234/239
0.92 (0.89 to 0.94) 88
(84 to 92)
261/296
98
(95 to 99)
234/239
0.93 (0.91 to 0.95) 93
(90 to 96)
277/296
98
(95 to 99)
233/239
0.96 (0.94 to 0.97)
Four consecutive uses of fistula 73
(67 to 78)
215/296
95
(92 to 98)
228/239
0.84 (0.81 to 0.87) 86
(82 to 90)
255/296
94
(90 to 96)
224/239
0.90 (0.87 to 0.92) 93
(89 to 96)
275/296
94
(90 to 96)
224/239
0.93 (0.91 to 0.95) 97
(94 to 99)
287/296
94
(90 to 96)
224/239
0.95 (0.94 to 0.97) 100
(98 to 100)
295/296
92
(87 to 95)
219/239
0.96 (0.94 to 0.97)
≥1 use of fistula 78
(73 to 83)
231/296

93
(88 to 96)
221/239
0.85 (0.82 to 0.88) 89
(85 to 92)
263/296
90
(85 to 94)
215/239
0.89 (0.87 to 0.92) 95
(91 to 97)
280/296
89
(84 to 92)
212/239
0.92 (0.89 to 0.94) 98
(95 to 99)
289/296
88
(84 to 92)
211/239
0.93 (0.91 to 0.95) 100
(99 to 10)
296/296
86
(81 to 90)
205/239
0.93 (0.91 to 0.95)

Sens., sensitivity; Spec., specificity; CI, confidence interval; TP, true positive; FN, false negative; TN, true negative; FN, false positive; AUC, area under the curve; HFM, Hemodialysis Fistula Maturation; Ref, reference; NAVAC, North America Vascular Access Consortium; KHI, Kidney Health Initiative; BPS, blood pump speed.